MX2016003002A - Methods of determining response to therapy. - Google Patents
Methods of determining response to therapy.Info
- Publication number
- MX2016003002A MX2016003002A MX2016003002A MX2016003002A MX2016003002A MX 2016003002 A MX2016003002 A MX 2016003002A MX 2016003002 A MX2016003002 A MX 2016003002A MX 2016003002 A MX2016003002 A MX 2016003002A MX 2016003002 A MX2016003002 A MX 2016003002A
- Authority
- MX
- Mexico
- Prior art keywords
- therapy
- methods
- determining response
- metadoxine
- response
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- RYKKQQUKJJGFMN-HVDRVSQOSA-N 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol;(2s)-5-oxopyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCC(=O)N1.CC1=NC=C(CO)C(CO)=C1O RYKKQQUKJJGFMN-HVDRVSQOSA-N 0.000 abstract 2
- 208000001914 Fragile X syndrome Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
The present invention relates generally to methods of determining the response to metadoxine therapy for the treatment of Fragile X Syndrome and other cognitive disorders. The invention also relates to identifying individuals that will be responsive to metadoxine therapy.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361875384P | 2013-09-09 | 2013-09-09 | |
| US14/038,258 US20150073023A1 (en) | 2013-09-09 | 2013-09-26 | Method Of Treating Fragile X Syndrome And Related Disorders |
| US201461991351P | 2014-05-09 | 2014-05-09 | |
| PCT/US2014/054816 WO2015035402A1 (en) | 2013-09-09 | 2014-09-09 | Methods of determining response to therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016003002A true MX2016003002A (en) | 2016-09-08 |
Family
ID=52629036
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016003006A MX2016003006A (en) | 2013-09-09 | 2014-09-09 | Methods of treating fragile x syndrome and related disorders. |
| MX2016003002A MX2016003002A (en) | 2013-09-09 | 2014-09-09 | Methods of determining response to therapy. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016003006A MX2016003006A (en) | 2013-09-09 | 2014-09-09 | Methods of treating fragile x syndrome and related disorders. |
Country Status (12)
| Country | Link |
|---|---|
| EP (2) | EP3043792A2 (en) |
| JP (2) | JP2016530536A (en) |
| KR (2) | KR20160078956A (en) |
| CN (2) | CN105917225A (en) |
| AU (2) | AU2014316779A1 (en) |
| CA (2) | CA2922901A1 (en) |
| EA (2) | EA201690559A1 (en) |
| IL (2) | IL244343A0 (en) |
| MX (2) | MX2016003006A (en) |
| SG (2) | SG11201601605YA (en) |
| TW (2) | TW201605443A (en) |
| WO (2) | WO2015033224A2 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109021022B (en) * | 2013-07-31 | 2021-04-16 | Udc 爱尔兰有限责任公司 | Luminescent diazabenzimidazole carbene metal complexes |
| US20150073023A1 (en) | 2013-09-09 | 2015-03-12 | Alcobra Ltd. | Method Of Treating Fragile X Syndrome And Related Disorders |
| CN108538365A (en) * | 2017-03-24 | 2018-09-14 | 华东师范大学 | A kind of self-closing disease sociability assessment system based on data analysis technique |
| CN112055587A (en) * | 2018-04-13 | 2020-12-08 | Healx有限公司 | Treatment of fragile X syndrome |
| KR20190121569A (en) * | 2018-04-18 | 2019-10-28 | 건국대학교 글로컬산학협력단 | Pharmaceutical Composition for Improving Fragile X Syndrome Comprising Agmatine or its derivatives |
| JP7387179B2 (en) | 2018-06-07 | 2023-11-28 | オービッド・セラピューティクス・インコーポレイテッド | (S)-3-amino-4-(difluoromethyleneyl)cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) in the treatment of developmental disorders. ) Use of cyclopentane-1-carboxylic acid and vigabatrin |
| JP7490064B2 (en) * | 2020-01-08 | 2024-05-24 | ニューロヴェンティ カンパニー リミテッド | Composition for treating fragile X syndrome or related developmental disorders containing Lislead compound as an active ingredient |
| US12396983B2 (en) | 2020-02-07 | 2025-08-26 | Neuroventi | Composition comprising rilmenidine compound as active ingredient for treatment of fragile X syndrome or related developmental disability |
| JOP20220338A1 (en) * | 2020-06-29 | 2023-01-30 | Zynerba Pharmaceuticals Inc | Treatment of fragile X syndrome with cannabidiol |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1131856B (en) | 1980-06-30 | 1986-06-25 | Baldacci Lab Spa | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALCOHOLIC INTOXICATIONS |
| AU2002236527A1 (en) * | 2000-11-30 | 2002-06-11 | The Health Research Institute | Nutrient supplements and methods for treating autism and for preventing the onset of autism |
| IL187159A0 (en) | 2007-07-03 | 2009-02-11 | Gur Megiddo | Use of metadoxine in relief of alcohol intoxication |
| MX2011013775A (en) * | 2009-06-25 | 2012-04-20 | Alcobra Ltd | A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition. |
-
2014
- 2014-09-05 TW TW103130856A patent/TW201605443A/en unknown
- 2014-09-05 TW TW103130859A patent/TW201606304A/en unknown
- 2014-09-09 CN CN201480060722.4A patent/CN105917225A/en active Pending
- 2014-09-09 WO PCT/IB2014/002398 patent/WO2015033224A2/en not_active Ceased
- 2014-09-09 AU AU2014316779A patent/AU2014316779A1/en not_active Abandoned
- 2014-09-09 EA EA201690559A patent/EA201690559A1/en unknown
- 2014-09-09 EP EP14830858.8A patent/EP3043792A2/en not_active Withdrawn
- 2014-09-09 MX MX2016003006A patent/MX2016003006A/en unknown
- 2014-09-09 MX MX2016003002A patent/MX2016003002A/en unknown
- 2014-09-09 JP JP2016540930A patent/JP2016530536A/en active Pending
- 2014-09-09 AU AU2014315026A patent/AU2014315026A1/en not_active Abandoned
- 2014-09-09 EP EP14776939.2A patent/EP3044589A1/en not_active Withdrawn
- 2014-09-09 KR KR1020167009040A patent/KR20160078956A/en not_active Withdrawn
- 2014-09-09 SG SG11201601605YA patent/SG11201601605YA/en unknown
- 2014-09-09 SG SG11201601830PA patent/SG11201601830PA/en unknown
- 2014-09-09 WO PCT/US2014/054816 patent/WO2015035402A1/en not_active Ceased
- 2014-09-09 CA CA2922901A patent/CA2922901A1/en not_active Abandoned
- 2014-09-09 CA CA2923421A patent/CA2923421A1/en not_active Abandoned
- 2014-09-09 JP JP2016539645A patent/JP2016530291A/en active Pending
- 2014-09-09 KR KR1020167009042A patent/KR20160086818A/en not_active Withdrawn
- 2014-09-09 CN CN201480049671.5A patent/CN105517546A/en active Pending
- 2014-09-09 EA EA201690557A patent/EA201690557A1/en unknown
-
2016
- 2016-02-29 IL IL244343A patent/IL244343A0/en unknown
- 2016-03-06 IL IL244453A patent/IL244453A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201606304A (en) | 2016-02-16 |
| WO2015033224A2 (en) | 2015-03-12 |
| CA2922901A1 (en) | 2015-03-12 |
| AU2014315026A1 (en) | 2016-03-24 |
| IL244343A0 (en) | 2016-04-21 |
| JP2016530536A (en) | 2016-09-29 |
| EP3044589A1 (en) | 2016-07-20 |
| IL244453A0 (en) | 2016-04-21 |
| CN105917225A (en) | 2016-08-31 |
| WO2015033224A3 (en) | 2015-07-02 |
| CN105517546A (en) | 2016-04-20 |
| KR20160086818A (en) | 2016-07-20 |
| KR20160078956A (en) | 2016-07-05 |
| CA2923421A1 (en) | 2015-03-12 |
| MX2016003006A (en) | 2016-06-10 |
| JP2016530291A (en) | 2016-09-29 |
| SG11201601830PA (en) | 2016-04-28 |
| AU2014316779A1 (en) | 2016-03-17 |
| SG11201601605YA (en) | 2016-04-28 |
| TW201605443A (en) | 2016-02-16 |
| WO2015035402A1 (en) | 2015-03-12 |
| EA201690559A1 (en) | 2016-08-31 |
| EA201690557A1 (en) | 2016-07-29 |
| EP3043792A2 (en) | 2016-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016003002A (en) | Methods of determining response to therapy. | |
| ZA201902141B (en) | Acid-alpha glucosidase variants and uses thereof | |
| IL273688A (en) | Evaluation and treatment of bradykinin-mediated disorders | |
| ZA201902140B (en) | Acid-alpha glucosidase variants and uses thereof | |
| IL239957A0 (en) | Evaluation, assays and treatment of pkal-mediated disorders | |
| MX2015006324A (en) | Methods for the manufacture of proteolytically processed polypeptides. | |
| PH12015501071A1 (en) | Combination therapy of anti-her3 antibodies | |
| IN2014DN05885A (en) | ||
| IL244182A0 (en) | Compositions, methods and systems for the treatment of cutaneous disorders | |
| MX2014014376A (en) | Anti-biotin antibodies and methods of use. | |
| IN2013MU00848A (en) | ||
| MX2016002027A (en) | Novel anti-fc-gamma receptor iib antibodies and uses thereof. | |
| IN2014DN07191A (en) | ||
| WO2015089503A3 (en) | Treating brain disorders and biomarkers related thereto | |
| EP3008211A4 (en) | Methods and kits for treating and classifying individuals at risk of or suffering from trap1 change-of-function | |
| WO2014201387A3 (en) | Methods of improving reproductive and respiratory health | |
| EA201501176A1 (en) | SUBSTITUTED BENZOXASOLES | |
| MX2016004333A (en) | Use of odiparcil in the treatment of a mucopolysaccharidosis. | |
| TH1501005802A (en) | Galactooligosaccharide composition for preventive use or treat cognitive disorders and emotional fluctuations in illness. Psychological or aging | |
| GB201315536D0 (en) | System for identifying and contacting people within eye contact range |